Endometriosis: a chronic, painful disease
=========================================

Endometriosis is a chronic, estrogen-dependent disease that affects approximately 10% of women of reproductive age, with a peak incidence in the age range of 25--30 years.[@b1-ijwh-3-175]--[@b3-ijwh-3-175] Endometriosis is characterized by the formation of endometriotic lesions outside the uterus, including the ovaries and other pelvic structures. These lesions cause a chronic, inflammatory reaction, which can lead to the formation of scar tissue and adhesions.[@b4-ijwh-3-175] Women with endometriosis frequently experience symptoms of dysmenorrhea, premenstrual pain, dyspareunia, and chronic fatigue.[@b5-ijwh-3-175] Endometriosis can also interfere with functioning of the bowel or bladder, depending on the site where endometriotic lesions develop. Up to 50% of women with endometriosis experience infertility.[@b6-ijwh-3-175] However, the clinical presentations of endometriosis can vary widely, and many affected women are asymptomatic.[@b7-ijwh-3-175] No clear relationship exists between the extent of endometriotic lesions and a woman's symptoms.

Quality of life studies show that symptoms of endometriosis impact on many aspects of a woman's life, including work and education, relationships, and social functioning.[@b8-ijwh-3-175]--[@b14-ijwh-3-175] As symptoms become more severe, quality of life is reduced further. In a recent international survey, women with endometriosis reported a substantial 38% reduction in work productivity, which was attributable primarily to reduced work effectiveness in the presence of pelvic pain.[@b15-ijwh-3-175] Endometriosis also impacts mental health, with one study showing that 87% of the women investigated with endometriosis had depressive symptoms and 88% had anxiety.[@b16-ijwh-3-175] The severity of anxiety symptoms correlated with the intensity of pain.

Endometriosis places a considerable economic burden on families and on society. Delays in diagnosis, high rates of hospital admission, surgical procedures, and incidences of comorbid conditions contribute to make endometriosis a more costly public health problem than other chronic conditions such as migraine and Crohn's disease.[@b9-ijwh-3-175],[@b17-ijwh-3-175]--[@b21-ijwh-3-175]

Diagnosis and treatment of endometriosis
========================================

Diagnosis
---------

Due to the variable presentation of endometriosis, there is typically a delay between the first appearance of symptoms and an accurate diagnosis. An international survey reported that this delay is, on average, seven years.[@b15-ijwh-3-175] Early diagnosis is an important objective, as endometriosis typically follows a progressive course characterized by a worsening of symptoms in the absence of effective treatment. Errors in diagnosis, with the potential for inappropriate therapy, are also common, creating anxiety and frustration, and contributing further to the burden of endometriosis.

A definitive diagnosis of endometriosis requires laparoscopy, ideally combined with confirmatory histology, to characterize endometriotic lesions.[@b4-ijwh-3-175],[@b22-ijwh-3-175] In practice, however, this invasive approach is considered unnecessary or inappropriate for many patients, and a presumptive diagnosis of endometriosis can be made from the symptoms alone.[@b4-ijwh-3-175]

Treatment
---------

There is no permanent cure for endometriosis. As stated by the American Society for Reproductive Medicine, "Endometriosis should be viewed as a chronic disease that requires a life-long management plan with the goal of maximizing the use of medical treatment and avoiding repeated surgical procedures."[@b23-ijwh-3-175] Women with endometriosis require ongoing, collaborative, supportive management of their condition, as well as an understanding of the significant impact that the condition can have on their quality of life.

The main aims of treatment are to alleviate pain and other symptoms, reduce endometriotic lesions, and improve the quality of life of affected individuals. A number of medical and surgical therapies are available to treat endometriosis, which may, on occasion, be used in combination. No single treatment is ideal for all patients and the management approach chosen should be directed to the individual needs of each patient. As endometriosis is a chronic disease, consideration should be given not only to the efficacy but also to the long-term safety and tolerability of the treatment options that are available.

### Surgery

Surgical intervention includes ablation of endometriotic lesions, removal of endometriotic cysts, and division of adhesions. Surgery can provide pain relief and enhance fertility, but this approach should be delayed for as long as possible due to the high risk of recurrence, which attains a rate of 40%--50% at five years.[@b24-ijwh-3-175] Medications administered postoperatively may reduce the risk of recurrence.

### Medical therapy

Nonsteroidal anti-inflammatory drugs are frequently used by women with endometriosis in an attempt to achieve analgesia, although clinical trial evidence to support the efficacy of these agents in endometriosis is lacking.[@b25-ijwh-3-175] A major limitation to the long-term use of nonsteroidal anti-inflammatory drugs is their significant side effects, including the risk of gastric ulceration and an antiovulatory effect when taken at mid-cycle.[@b4-ijwh-3-175],[@b25-ijwh-3-175]

Specific medical therapies that are approved for the treatment of endometriosis include gonadotropin-releasing hormone (GnRH) agonists, danazol, and certain progestins. These agents and the combined oral contraceptives (COCs) share a common hormonal mechanism of action in endometriosis.

COCs are widely used to treat the symptoms of endometriosis, although they are not approved for this indication in the majority of countries because of the absence of supportive trial evidence.[@b26-ijwh-3-175] For the same reason, practice guidelines can offer limited guidance on the optimal COC regimens in endometriosis.[@b27-ijwh-3-175] A recently published review notes that the putative biological effects for COCs include both inhibition of endometrial cell implantation but also a protective effect against endometrial lesion necrosis.[@b28-ijwh-3-175] Clinical experience indicates that COCs may be used with safety in many women for the long-term treatment of endometriosis. However, a common problem with long-term continuous COC regimens is breakthrough bleeding. This is often treated by discontinuing the COC for a few days and then restarting therapy.

GnRH agonists are an established therapy for endometriosis that can be administered via either intramuscular, subcutaneous, or intranasal routes.[@b29-ijwh-3-175] Depot formulations are available. Although GnRH agonists provide effective pain relief and reduce the progression of endometriotic implants,[@b29-ijwh-3-175] the hypoestrogenic state that they induce is associated with effects such as accelerated bone mineral density loss, hot flushes, and vaginal dryness.[@b30-ijwh-3-175] In consequence, the use of GnRH agonists is limited to six months in the absence of "add-back" therapy with steroids. The optimal regimens for add-back therapy are not yet established.[@b18-ijwh-3-175],[@b31-ijwh-3-175] For younger women who have not yet reached maximum bone density, guidelines recommend a careful consideration of the use of GnRH agonists due to their bone demineralizing effects.[@b4-ijwh-3-175]

Danazol is an androgenic steroid that is effective in treating the signs and symptoms of endometriosis, but its use is limited by adverse effects on lipid metabolism and by weight gain, edema, acne, vaginal dryness, hot flushes, oily skin, hirsutism, liver toxicity, and breast atrophy.[@b18-ijwh-3-175],[@b32-ijwh-3-175] Because of these effects, danazol has today been superseded in many countries by alternative agents.

Oral, parenteral, intrauterine, or implantable progestins have been used for decades in the treatment of endometriosis, although for many of these agents there is a lack of supportive evidence from controlled clinical trials. Dose-finding data are lacking for most progestins, and there are few comparative data to indicate the benefits of one progestin over another.

The progestins that are approved for use in endometriosis vary between countries. A notable example is medroxyprogesterone acetate injectable suspension (Depo-subQ Provera 104™, Pfizer, New York, NY), which was approved recently by the US Food and Drug Administration for the treatment of endometriosis based on active comparator-controlled trial data. This medication carries a black box warning concerning possible bone mineral loss. The preparation is not available in Europe.

When administered continuously, progestins are effective in many women for the management of pain and other symptoms of endometriosis, with beneficial effects also relating to amenorrhea and anovulation. However, certain progestins are effective in endometriosis only at high doses when compared with use in other indications,[@b33-ijwh-3-175],[@b34-ijwh-3-175] which may increase the likelihood of adverse effects, such as weight gain and androgenic effects, and elevate the risk of cardiovascular adverse events.

Dienogest in endometriosis
==========================

Dienogest is an oral progestin that has been investigated systematically for the treatment of endometriosis in dose-ranging, placebo-controlled, active comparator-controlled, and long-term trials performed in Europe and Japan ([Figure 1](#f1-ijwh-3-175){ref-type="fig"}). Based on this trial evidence, dienogest has received approval as a monotherapy for the treatment of endometriosis in Europe, Japan, Australia, and Singapore.

Preclinical studies
-------------------

Dienogest demonstrates a number of characteristics in preclinical studies that are relevant to its use in endometriosis. Pharmacologically, dienogest combines the advantages of the 19-norprogestin and the progesterone derivative classes.[@b35-ijwh-3-175],[@b36-ijwh-3-175] Dienogest binds to the progesterone receptor with high specificity, and produces a potent progestogenic effect related to the high circulating levels of the unbound molecule.[@b37-ijwh-3-175] Binding affinities of dienogest for estrogen, glucocorticoid, and mineralocorticoid receptors are negligible. Unlike other agents in the 19-norprogestin class, dienogest lacks androgenic effects; rather, dienogest has beneficial antiandrogenic properties typical of the progesterone derivatives, which are associated with minimal changes in lipid and carbohydrate levels.[@b38-ijwh-3-175],[@b39-ijwh-3-175]

Dienogest is almost completely absorbed, and has a high bioavailability after oral administration, similar to other 19-norprogestins. Its relatively short half-life of 10 hours means there is no risk of accumulation after repeated dosing. The majority of orally administered dienogest is excreted within 24 hours, mainly in urine.

Dienogest reduces endometriotic lesions through a number of biological mechanisms. Dienogest is associated with relatively moderate inhibition of gonadotropin secretion, leading to a modest reduction in the endogenous production of estradiol.[@b40-ijwh-3-175] When given continuously, dienogest induces a hypoestrogenic, hypergestagenic local endocrine environment, causing a decidualization of endometrial tissue followed by atrophy of the endometriotic lesions. Animal studies indicate that dienogest may also reduce plasma estradiol levels directly, through inducing apoptosis of granulosa cells in the ovary.[@b41-ijwh-3-175]

A recent pharmacokinetic study confirmed the moderate suppression of estradiol levels, remaining within the lower end of the normal physiological range, in women volunteers administered dienogest at doses of 0.5--3 mg daily.[@b42-ijwh-3-175] In this study, ovarian activity was effectively suppressed by the 2 mg and 3 mg doses, with a rapid return to ovulation after cessation of dienogest administration.

In exploratory models of endometriosis, dienogest also demonstrates antiproliferative, anti-inflammatory, and antiangiogenic effects.[@b36-ijwh-3-175],[@b43-ijwh-3-175]--[@b45-ijwh-3-175] In vitro and animal studies show that dienogest has a direct inhibitory effect on the proliferation of endometrial-like tissue that is independent of actions via the progesterone receptor.[@b46-ijwh-3-175]--[@b49-ijwh-3-175] Indirect anti-inflammatory activity through modification of proinflammatory markers has been demonstrated for dienogest in in vitro and in vivo experiments.[@b50-ijwh-3-175] A further potential mechanism of action for dienogest is inhibition of angiogenesis, which represents an essential stage in the development of endometriotic lesions. Oral administration of dienogest significantly suppressed angiogenesis in a mouse model.[@b45-ijwh-3-175] The molecular mechanisms underlying these effects continue to be explored.[@b48-ijwh-3-175]--[@b51-ijwh-3-175]

Clinical studies
----------------

Clinical studies of dienogest with durations between 12 and 24 weeks have provided information on optimal dosing and on efficacy and safety characteristics that are relevant to the long-term management of endometriosis.

The optimal daily dose of dienogest for treating endometriosis was investigated in an open-label, randomized, multicenter, 24-week, dose-ranging study in Europe.[@b39-ijwh-3-175] Sixty-eight women with endometriosis stage I--III at laparoscopy (ie, with minimal to moderate disease) were randomly assigned to treatment with dienogest 1, 2, or 4 mg once daily. Randomization to the 1 mg group was halted prematurely because of unsatisfactory bleeding patterns. Laparoscopy showed that dienogest at 2 mg and 4 mg daily significantly reduced endometriotic lesions. In addition, dienogest at both these doses improved patient-reported symptoms, including the intensity of dyspareunia, dysmenorrhea, and diffuse pelvic pain. The 2 mg and 4 mg dienogest doses were generally well tolerated and rates of discontinuations due to adverse events were low. Irregular uterine bleeding was experienced by 55.2% in the 2 mg group and 68.6% in the 4 mg group, with a trend to decreased intensity over time in both groups. Based on these outcomes, dienogest at 2 mg once daily was recommended as the optimal dose in the treatment of endometriosis.

In support of these findings, a Japanese study investigated dienogest at daily doses of 1 mg, 2 mg, and 4 mg for 24 weeks in 183 women with endometriosis.[@b52-ijwh-3-175] The 2 mg and 4 mg daily doses were equivalent in efficacy, measured as a global improvement in subjective symptoms. While safety assessments indicated no dose-related differences, reductions in estradiol levels associated with the 4 mg dose indicated that 2 mg daily may offer least potential for adverse effects on bone mineral density. Mean serum estradiol concentrations at between eight weeks and the end of treatment in this study were 84.5, 37.4, and 26.2 pg/mL for dienogest doses of 1, 2, and 4 mg/day, respectively. A serum estradiol concentration in the range of 30--50 pg/mL is considered to fulfill the requirements of the estrogen threshold hypothesis,[@b53-ijwh-3-175] by which estrogen levels are suppressed sufficiently to inhibit endometriotic lesion growth, but are adequate to prevent hypoestrogenic side effects such as bone mineral loss. Of relevance to long-term compliance, 77% of the patients commented that they "wanted" or "definitely wanted" to use the dienogest 2 mg daily dose again.

The effectiveness of dienogest at the 2 mg daily dose was compared against placebo in a 12-week, randomized trial using a range of tools for measuring changes in symptoms and quality of life. The study enrolled 198 women with stage I--IV (ie, minimal to severe) endometriosis and an endometriosis-associated pelvic pain score of at least 30 mm on a visual analog scale (measured on a scale of 0--100 mm), which represents a well validated tool for the measurement of pain.[@b54-ijwh-3-175],[@b55-ijwh-3-175] Dienogest produced a statistically significant decrease in the mean visual analog score compared with placebo, with a between-group difference of 12.3 mm in favor of dienogest (*P* \< 0.0001). Biberoglu and Behrman scale scores supported the visual analog scores by demonstrating greater reductions in the intensity of symptoms and signs in the dienogest group compared with placebo. The Clinical Global Impression scale, a measure of overall improvement, showed that 52.9% of the patients treated with dienogest were assessed by physicians to be "very much improved/much improved" at week 12, compared with 22.9% in the placebo group. Quality of life analyses based on the Short Form 36 Health Survey questionnaire, a non-disease-specific tool used widely in clinical trials, showed that dienogest was associated with significantly greater improvement in "bodily pain" than placebo treatment. Dienogest was generally well tolerated in this trial, with no serious or unexpected adverse events, and few events related to therapy. Estradiol levels were modestly suppressed, and profiles of uterine bleeding in the dienogest group were comparable with the placebo group.

Three studies of 16--24 weeks' duration have directly compared dienogest against GnRH agonists, a standard therapy in endometriosis.[@b56-ijwh-3-175]--[@b58-ijwh-3-175] In a 24-week, randomized study of 252 women with endometriosis in Europe, dienogest 2 mg once daily and leuprolide acetate at standard dose (3.75 mg, depot intramuscular injection every four weeks) provided comparable, continuous reductions in pelvic pain measured by visual analog score. By week 24, reductions in mean visual analog score were 47.5 mm for dienogest and 46.0 mm for leuprolide acetate. Consistent with the visual analog score changes, dienogest and leuprolide acetate induced similar decreases in the intensity of symptoms and physical findings assessed by Biberoglu and Behrman scores. Short Form 36 Health Survey scores showed a trend to greater improvement in both physical and mental health in the dienogest than the leuprolide acetate group. Effects of estrogen deprivation were substantially more common in the leuprolide acetate group than dienogest group, including numbers of days with hot flushes/week (mean 4.7 versus 0.82, respectively), while bleeding episodes were suppressed less with dienogest than leuprolide acetate. The leuprolide acetate group showed a reduction in mean lumbar bone mineral density, while, in the dienogest group, lumbar bone mineral density showed a small increase (*P* = 0.0003 versus leuprolide acetate).[@b57-ijwh-3-175]

Dienogest 1 mg twice daily was compared with triptorelin 3.75 mg (depot intramuscular injection every four weeks) as a postoperative medication in a 16-week, multicenter, open, randomized trial of 142 women with stage II--IV endometriosis.[@b56-ijwh-3-175] The two medications were equally effective in improving endometriosis symptoms and signs, and laparoscopy scores. Hot flushes were reported in 61.2% of women receiving the GnRH agonist compared with 9.6% of women treated with dienogest. Irregular bleeding was the most common complication in the dienogest group (61.6% versus 25.4% with GnRH agonist).

The third comparative trial including a GnRH agonist was a 24-week, randomized, double-blind, multicenter study comparing dienogest 2 mg once daily against intranasal buserelin acetate 300 μg three times daily, which was performed in Japan in 271 women with confirmed endometriosis. [@b58-ijwh-3-175] Dienogest was as effective as buserelin acetate in reducing endometriosis symptoms and lesion size at laparoscopy. Greatest changes in quality of life (assessed by Short Form 36 Health Survey score) in both groups were improvements in bodily pain, with a trend to greater improvement in the dienogest group. Mean lumbar bone mineral density decreased in both groups in this population, with a significantly greater reduction in the buserelin acetate group (*P* = 0030). Consistent with the other comparative trials, dienogest was associated more frequently with irregular bleeding but less frequently with hot flushes than the GnRH agonist.

Notably, each of the trials that investigated dienogest 2 mg daily described adverse effects of generally mild to moderate intensity which were associated with low rates of treatment discontinuation (eg, 5.0%[@b57-ijwh-3-175] and 4.4%[@b58-ijwh-3-175] over 24-week treatment durations). Bleeding episodes decreased in number and intensity over time, and were associated with no discontinuations in these trials.[@b57-ijwh-3-175],[@b58-ijwh-3-175]

An open-label pilot study of dienogest at the higher dose of 10 mg twice daily for 24 weeks provides additional information on the safety of this medication.[@b59-ijwh-3-175],[@b60-ijwh-3-175] Dienogest at 20 mg daily had no clinically relevant effect on thyroid or adrenal function, electrolyte balance, or hematopoiesis in the 21 women with stage I--IV endometriosis who participated. In addition, dienogest at this high dose had no adverse effects on lipid metabolism, liver enzymes, fasting insulin, or glucose. No menopausal symptoms and no adverse androgen-related effects were reported. These observations, demonstrating that dienogest has a favorable safety and tolerability profile even at 20 mg daily (ie, 10 times the recommended dose), support the conclusion that the recommended dose of 2 mg once daily will have a similar beneficial profile.

Dienogest and fertility considerations
======================================

The majority of women suffering from endometriosis are of reproductive age and so may require contraception. Based on the available data, dienogest provides complete ovulation inhibition at a daily dose of 2 mg.[@b37-ijwh-3-175],[@b42-ijwh-3-175],[@b61-ijwh-3-175] However, dienogest monotherapy was not developed as a contraceptive, and women taking dienogest as a treatment for endometriosis are advised to use nonhormonal methods of contraception.

Women with endometriosis may desire pregnancy once sufficient pain relief is achieved. Recent pharmacodynamic data in volunteers indicate that ovarian activity resumes rapidly (range 1--43 days) after cessation of dienogest.[@b42-ijwh-3-175] These observations support studies that describe a prompt return to fertility (eg, mean about 30 days) and include cases of successful pregnancy in women with endometriosis following the cessation of dienogest treatment 2 mg daily for durations up to one year.[@b52-ijwh-3-175],[@b62-ijwh-3-175],[@b63-ijwh-3-175]

As with other progestins, there are limited data on the use of dienogest in pregnant women. The available data do not indicate harmful effects for dienogest with respect to reproductive toxicity and reveal no special risks on pregnancy. However, dienogest should not be administered to pregnant women because there is no need to treat endometriosis during pregnancy.[@b64-ijwh-3-175]

Dienogest for the long-term treatment of endometriosis
======================================================

Effective management of endometriosis over the longer term is an important objective. The painful symptoms and impairment in quality of life associated with endometriosis may persist or deteriorate in the absence of effective treatment. Recurrence is frequent even after successful surgery, while there are only limited trial data to confirm the efficacy and safety of long-term treatment for many medications used in endometriosis.

Dienogest has been investigated as a long-term treatment of endometriosis in two large trials performed in Europe and Japan, which included assessments of efficacy, change in quality of life, safety, and tolerability.

Women who completed the 12-week placebo-controlled study in Europe[@b54-ijwh-3-175] were offered the opportunity to enter an open-label extension study of dienogest for up to 53 additional weeks, providing an overall treatment period of up to 65 weeks.[@b62-ijwh-3-175] Notably, of the 188 women completing the placebo-controlled study, a large proportion (n = 168, 89%) consented to enter the long-term extension study. The intensity of pain showed significant, sustained improvements during the long-term study, in addition to the improvements associated with dienogest during the placebo-controlled phase. Mean visual analog scores decreased from 56.9 mm at baseline of the placebo-controlled study to 34.1 mm at baseline of the long-term study, to 11.5 mm at the end of the 53 additional weeks of treatment ([Figure 2](#f2-ijwh-3-175){ref-type="fig"}). During a 24-week treatment-free period following the long-term study, visual analog scores increased only moderately, suggesting that dienogest induces a beneficial effect that may persist after treatment cessation. Short Form 36 Health Survey scores during the treatment-free period indicated minimal changes in physical or mental indices of quality of life over six months after cessation of dienogest.

During the long-term study, laboratory parameters, vital signs, and body weight remained stable or underwent minimal changes. Adverse effects considered potentially treatment-related developed in 16.1% of women, including breast discomfort (4.2%), nausea (3.0%), and irritability (2.4%). The maximal intensity of treatment-related adverse events was mild or moderate in 92.5% of cases. In agreement with trends observed in the 12- and 24-week studies, the intensity and frequency of bleeding reduced progressively over the course of the long-term study. During post-treatment follow-up, bleeding returned to normal intensity and cyclic patterns resumed within 4--6 weeks. Treatment compliance during the long-term study was high (98%) and discontinuation rates due to adverse events or lack of efficacy were both low (2.4% and 0.6%, respectively).

The results of this long-term study performed in Europe are supported by a 52-week, nonrandomized trial of dienogest 2 mg daily conducted in Japan on 135 women with confirmed endometriosis.[@b63-ijwh-3-175] Global improvement was measured by change in the severity of five subjective symptoms (lower abdominal pain, lumbago, dyschezia, dyspareunia, and pain on vaginal examination) and two objective findings (induration involving pouch of Douglas and uterine mobility). Moderate or marked global improvement was recorded in 72.5% of patients after 24 weeks and in 90.6% after 52 weeks of dienogest treatment ([Figure 3](#f3-ijwh-3-175){ref-type="fig"}). Changes in visual analog score for lower abdominal pain and lumbago decreased progressively, while the proportion of patients demonstrating a reduction in cyst size \>25% was 85% at 52 weeks. Quality of life assessments using the Short Form 36 Health Survey score indicated improvements in bodily pain by 23.57 and 27.37 points (on a 100-point scale) at 24 and 52 weeks, respectively, compared with baseline. Patient satisfaction with dienogest at the end of treatment was high, with 88.9% of women responding that they were "certainly willing" or "would prefer" to use dienogest again.

The most commonly reported treatment-related adverse event was metrorrhagia (71.9%), followed by headaches (18.5%) and constipation (10.4%). None of the treatment-related adverse events was rated as serious. Metrorrhagia resolved in 96 of the 97 affected patients either during the study or within two months of study cessation. The frequency of bleeding lessened as treatment progressed, so that 40.5% of women were experiencing no bleeding by 49--52 weeks. Resumption of menses was confirmed in all women at the end of the study. The discontinuation rate due to treatment-related adverse events was 5.2%. Lumbar bone mineral density decreased by 1.7 ± 2.2% between baseline and week 52, with the greatest change in the first 24 weeks. The authors noted that this bone mineral density change may be considered mild and not significantly greater than that observed in untreated women of similar age. No biochemical markers of bone metabolism indicated changes outside the normal reference range.

Recently, a small open-label, nonrandomized study performed in Japan has investigated continued dienogest 2 mg/day for 12 months (n = 33 women) in comparison with sequential treatment including GnRH agonist (leuprorelin acetate or buserelin acetate) for 4--6 months followed by dienogest 1 mg/day for 12 months (n = 38).[@b65-ijwh-3-175] Continued dienogest significantly reduced the mean visual analog scores for dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia at six and 12 months, equivalent to the score reductions achieved with GnRH agonist followed by dienogest. For approximately 40% of women in the sequential treatment group, the dienogest dose was increased from 1 mg to 1.5--2 mg/day to optimize bleeding control. Consistent with other studies, uterine bleeding was significantly reduced in the second compared with the first six months of dienogest treatment. The divergence in dienogest dose hinders the interpretation of bleeding rates across the treatment groups. The authors concluded that dienogest represents a practical and efficient long-term therapy in patients who respond to GnRH agonist therapy. The data may be interpreted also to indicate that continued long-term dienogest is as effective for pain relief as a GnRH agonist followed by dienogest therapy.

Discussion
==========

Effective long-term management of endometriosis is a significant clinical objective in view of the debilitating nature of this often chronic condition. Among current management approaches, recurrence is common after surgery, while evidence to support the efficacy and safety of many medications is lacking. GnRH agonists, a standard medication in endometriosis, may not be administered continuously for more than six months in the absence of add-back therapy because of the deleterious hypoestrogenic effects.

Dienogest is a progestin investigated for the treatment of endometriosis. Dienogest at a dose of 2 mg daily has been studied extensively in clinical trial programs performed in Europe and Japan, including two studies with treatment durations of up to 65 weeks. These studies demonstrated that dienogest has an efficacy, safety, and tolerability profile that is favorable for long-term use. The intensity of pain associated with endometriosis decreased progressively, adverse events (mostly mild or moderate in intensity) were predictable and associated with low discontinuation rates, and bleeding irregularities reduced in intensity and frequency over time. Following cessation of dienogest treatment, menses returned to normal.

The impact of endometriosis on a woman's quality of life is substantial and wide ranging. Quality of life assessments in the dienogest studies indicated that improvements in both physical and mental indices were attained within 12-week and 24-week treatment durations, and that these benefits were sustained in studies of up to one year.

Also of major significance to clinical practice, compliance with dienogest treatment was high and rates of discontinuation due to adverse events were low in these studies. Contributors to this favorable compliance may include the efficacy of dienogest for symptom control and the predictability of adverse effects, which can be communicated to patients before treatment initiation. Large proportions of the women who were questioned expressed a willingness to continue dienogest treatment.

Together, the dienogest study programs performed in Europe and Japan indicate that dienogest represents a promising new medication for the long-term management of endometriosis.
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